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Abstract 
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors block DNA damage repair and may thereby 
enhance the clinical activity of DNA-damaging chemotherapy. Homologous recombination is defective 
in BRCA1/2-mutated tumors, leading to more error-prone mechanisms of DNA repair and increased 
sensitivity to PARP inhibition. V is a potent PARP inhibitor that enhances the antitumor activity of 
platinum agents in preclinical models. This phase 2 trial (NCT01506609) investigated the safety and 
efficacy of V+C/P or V+ temozolomide (TMZ) vs Plc+C/P in pts with locally recurrent or metastatic breast 
cancer harboring a BRCA1 or BRCA2 mutation. Results of the V+C/P and Plc+C/P arms are presented; 
V+TMZ results will be presented separately. 
Methods: Pts ≥18 years with histologically confirmed locally recurrent or metastatic breast cancer were 
randomized 1:1:1 to: 1) V 40 mg BID D1–7+TMZ, 28-D cycle; 2) V 120 mg BID D1–7+C AUC 6, D3 and P 
175 mg/m2, D3, 21-D cycle; or 3) Plc BID D1–7+C/P. Key eligibility criteria included 
deleterious BRCA1/2 mutation, ≤2 prior chemotherapies for metastatic disease, no prior platinum agent, 
and no CNS metastases. Randomization was stratified by hormone receptor status, prior cytotoxic 
therapy, and ECOG PS. The primary endpoint was progression-free survival (PFS) per RECIST 1.1 of each 
V arm vs Plc+C/P by independent review. Primary analysis occurred at the 112th PFS event in the V+C/P 
and Plc+C/P arms. Overall survival (OS), objective response rate (ORR), tolerability, and quality of life 
were also evaluated. 
Results: A total of 196 pts (193 BRCA+ per central lab) were randomized to receive double-blinded 
V+C/P (n=97) or Plc+C/P (n=99). Baseline demographics and disease characteristics were balanced 
across all treatment arms. Median study drug exposure was 10 cycles for Plc+C/P and 12 cycles for 
V+C/P. The V+C/P arm demonstrated numeric improvements for both PFS and OS compared to the 
Plc+C/P arm; improvement in ORR was statistically significant (Table 1). There was no meaningful 
increase of toxicity with addition of V. The most common treatment-emergent adverse events (AEs) 
with Plc+C/P or V+C/P were neutropenia (74%/74%), thrombocytopenia (70%/71%), and nausea 
(58%/71%). Grade ≥3 AEs in ≥30% of pts were neutropenia (55%/56%) and thrombocytopenia 
(26%/31%), respectively. There was no difference in the use of G-CSF with addition of V. Significant 
improvements in fatigue, pain, and insomnia (all P<0.05) were observed with V+C/P vs Plc+C/P. 
Conclusions: This is the first randomized phase 2 trial of a PARP inhibitor in combination with platinum-
based therapy for treatment of BRCA1/2-mutated advanced breast cancer. V+C/P demonstrated 
significantly higher ORR and symptom improvement compared to Plc+C/P, with nonsignificant trends for 
improved OS and PFS. Phase 3 trials are ongoing. 
Efficacy (ITT population – BRCA mutation) Plc+C/P, n=98 V+C/P, n=95 HR (95% CI); P value 
PFS(mo, 95% CI) 12.3 (9.3–14.5) 14.1 (11.5–16.2) 0.789 (0.536–1.162); 0.231 
OS (mo, 95% CI) 25.0 (18.1–34.8) 28.5 (22.4–NR) 0.725 (0.468–1.121); 0.148 
ORR, % (95% CI) 61.3 (49.7–71.9) 77.8 (66.4–86.7) P=0.027 
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